Hutchmed (china) Ltd key statistics and ratios

In fiscal 2025, Hutchmed (china) Ltd had return on equity of 45.7%, an operating margin of -7.1%, debt equal to 9.5% of equity and a current ratio of 4.96. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Hutchmed (china) Ltd: financial ratios, annual
Fiscal year	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	—	—	—	—	—	—	—	—	27.0%	54.1%	44.6%	38.7%
Operating margin	−20.9%	−5.5%	−21.6%	−22.1%	−43.3%	−71.4%	−86.3%	−92.2%	−95.6%	2.2%	−6.9%	−7.1%
Net margin	−8.4%	4.5%	5.4%	−11.1%	−34.9%	−51.7%	−55.2%	−54.7%	−84.6%	12.0%	6.0%	83.3%
Free-cash-flow margin	5.3%	−7.1%	−6.4%	−5.8%	−18.3%	−43.7%	−30.7%	−62.0%	−71.6%	22.3%	−2.8%	−14.4%
Return on equity	−12.8%	11.4%	8.7%	−8.3%	−17.6%	−31.3%	−32.6%	−26.5%	−45.2%	15.0%	5.1%	45.7%
Return on assets	—	3.5%	4.1%	−5.7%	−13.2%	−21.3%	−21.1%	−18.6%	−30.0%	8.7%	3.0%	30.2%
Asset turnover	—	0.78	0.76	0.51	0.38	0.41	0.38	0.34	0.35	0.73	0.49	0.36
Current ratio	—	1.10	1.76	4.13	4.33	2.80	3.35	3.89	2.37	2.72	2.83	4.96
Debt to equity	0.0%	87.5%	36.2%	6.5%	6.9%	9.3%	5.6%	2.7%	3.0%	15.1%	14.0%	9.5%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	24.2x	n/m	n/m
Effective tax rate	—	11.9%	21.1%	—	—	—	—	—	—	7.7%	—	12.8%
R&D as % of revenue	34.3%	26.6%	30.9%	31.3%	53.3%	67.4%	76.7%	84.0%	90.7%	36.0%	33.7%	27.0%
Capital spending as % of revenue	4.3%	1.9%	2.0%	2.1%	3.0%	4.2%	3.5%	4.6%	8.6%	3.9%	2.8%	2.6%
Free cash flow ÷ net income	—	−159.0%	−118.8%	—	—	—	—	—	—	185.2%	−46.2%	−17.2%
Dividends and buybacks ÷ free cash flow	—	—	—	—	—	—	—	—	—	4.9%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · December 31, 2025

What it owns · $1.8bn

Short-term assets $1.6bnLonger-term assets $186m

What it owes, and who funded it · $1.7bn

Short-term liabilities $316mLonger-term liabilities $186mShareholders' equity $1.2bn

Short-term assets cover short-term liabilities $1.6bn of assets due within a year against $316m of liabilities due within a year.
Short-term assets cover long-term liabilities $1.6bn short-term assets against $186m of longer-dated liabilities.
More cash than debt $71m of cash against $93m of debt.
Debt below 40% of shareholders' equity Debt is 8% of equity.
Debt burden no higher than five years ago Debt to equity moved from 6% to 8% over five years.
A year's operating cash flow covers at least 20% of debt −$65m of operating cash flow against $93m of debt.
Operating profit covers interest at least five times over Operating income of −$39m against $3m of interest.

From Hutchmed (china) Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ADMA vs HCM HCM vs TARS HCM vs MIRM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Hutchmed (china) Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Hutchmed (china) Ltd.